Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Evidence about the efficacy and safety of statin treatment in high-risk patients with hypercholesterolemia is available for some populations, but not for ethnic Chinese. To test the hypothesis that treatment with pitavastatin (2 mg/day) is not inferior to treatment with atorvastatin (10 mg/day) for...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3788128?pdf=render |
| _version_ | 1828458136594284544 |
|---|---|
| author | Ping-Yen Liu Liang-Yu Lin Hung-Ju Lin Chien-Hsun Hsia Yi-Ren Hung Hung-I Yeh Tao-Cheng Wu Ju-Yi Chen Kuo-Liong Chien Jaw-Wen Chen |
| author_facet | Ping-Yen Liu Liang-Yu Lin Hung-Ju Lin Chien-Hsun Hsia Yi-Ren Hung Hung-I Yeh Tao-Cheng Wu Ju-Yi Chen Kuo-Liong Chien Jaw-Wen Chen |
| author_sort | Ping-Yen Liu |
| collection | DOAJ |
| description | Evidence about the efficacy and safety of statin treatment in high-risk patients with hypercholesterolemia is available for some populations, but not for ethnic Chinese. To test the hypothesis that treatment with pitavastatin (2 mg/day) is not inferior to treatment with atorvastatin (10 mg/day) for reducing low-density lipoprotein cholesterol (LDL-C), a 12-week multicenter collaborative randomized parallel-group comparative study of high-risk ethnic Chinese patients with hypercholesterolemia was conducted in Taiwan. In addition, the effects on other lipid parameters, inflammatory markers, insulin-resistance-associated biomarkers and safety were evaluated.Between July 2011 and April 2012, 251 patients were screened, 225 (mean age: 58.7 ± 8.6; women 38.2% [86/225]) were randomized and treated with pitavastatin (n = 112) or atorvastatin (n = 113) for 12 weeks. Baseline characteristics in both groups were similar, but after 12 weeks of treatment, LDL-C levels were significantly lower: pitavastatin group = -35.0 ± 14.1% and atorvastatin group = -38.4 ± 12.8% (both: p < 0.001). For the subgroup with diabetes mellitus (DM) (n = 125), LDL-C levels (-37.1 ± 12.9% vs. -38.0 ± 13.1%, p = 0.62) were similarly lowered after either pitavastatin (n = 63) or atorvastatin (n = 62) treatment. Triglycerides, non-high density lipoprotein cholesterol, and apoprotein B were similarly and significantly lower in both treatment groups. In non-lipid profiles, HOMA-IR and insulin levels were higher to a similar degree in both statin groups. Hemoglobin A1C was significantly (p = 0.001) higher in the atorvastatin group but not in the pitavastatin group. Both statins were well tolerated, and both groups had a similar low incidence of treatment-emergent adverse events.Both pitavastatin (2 mg/day) and atorvastatin (10 mg/day) were well tolerated, lowered LDL-C, and improved the lipid profile to a comparable degree in high-risk Taiwanese patients with hypercholesterolemia.ClinicalTrials.gov NCT01386853 http://clinicaltrials.gov/ct2/show/NCT01386853?term=NCT01386853&rank=1. |
| first_indexed | 2024-12-11T01:19:17Z |
| format | Article |
| id | doaj.art-1cabbbb7ae574e3c9242b6ebf695b10c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T01:19:17Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1cabbbb7ae574e3c9242b6ebf695b10c2022-12-22T01:25:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7629810.1371/journal.pone.0076298Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).Ping-Yen LiuLiang-Yu LinHung-Ju LinChien-Hsun HsiaYi-Ren HungHung-I YehTao-Cheng WuJu-Yi ChenKuo-Liong ChienJaw-Wen ChenEvidence about the efficacy and safety of statin treatment in high-risk patients with hypercholesterolemia is available for some populations, but not for ethnic Chinese. To test the hypothesis that treatment with pitavastatin (2 mg/day) is not inferior to treatment with atorvastatin (10 mg/day) for reducing low-density lipoprotein cholesterol (LDL-C), a 12-week multicenter collaborative randomized parallel-group comparative study of high-risk ethnic Chinese patients with hypercholesterolemia was conducted in Taiwan. In addition, the effects on other lipid parameters, inflammatory markers, insulin-resistance-associated biomarkers and safety were evaluated.Between July 2011 and April 2012, 251 patients were screened, 225 (mean age: 58.7 ± 8.6; women 38.2% [86/225]) were randomized and treated with pitavastatin (n = 112) or atorvastatin (n = 113) for 12 weeks. Baseline characteristics in both groups were similar, but after 12 weeks of treatment, LDL-C levels were significantly lower: pitavastatin group = -35.0 ± 14.1% and atorvastatin group = -38.4 ± 12.8% (both: p < 0.001). For the subgroup with diabetes mellitus (DM) (n = 125), LDL-C levels (-37.1 ± 12.9% vs. -38.0 ± 13.1%, p = 0.62) were similarly lowered after either pitavastatin (n = 63) or atorvastatin (n = 62) treatment. Triglycerides, non-high density lipoprotein cholesterol, and apoprotein B were similarly and significantly lower in both treatment groups. In non-lipid profiles, HOMA-IR and insulin levels were higher to a similar degree in both statin groups. Hemoglobin A1C was significantly (p = 0.001) higher in the atorvastatin group but not in the pitavastatin group. Both statins were well tolerated, and both groups had a similar low incidence of treatment-emergent adverse events.Both pitavastatin (2 mg/day) and atorvastatin (10 mg/day) were well tolerated, lowered LDL-C, and improved the lipid profile to a comparable degree in high-risk Taiwanese patients with hypercholesterolemia.ClinicalTrials.gov NCT01386853 http://clinicaltrials.gov/ct2/show/NCT01386853?term=NCT01386853&rank=1.http://europepmc.org/articles/PMC3788128?pdf=render |
| spellingShingle | Ping-Yen Liu Liang-Yu Lin Hung-Ju Lin Chien-Hsun Hsia Yi-Ren Hung Hung-I Yeh Tao-Cheng Wu Ju-Yi Chen Kuo-Liong Chien Jaw-Wen Chen Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS ONE |
| title | Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). |
| title_full | Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). |
| title_fullStr | Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). |
| title_full_unstemmed | Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). |
| title_short | Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). |
| title_sort | pitavastatin and atorvastatin double blind randomized comparative study among high risk patients including those with type 2 diabetes mellitus in taiwan papago t study |
| url | http://europepmc.org/articles/PMC3788128?pdf=render |
| work_keys_str_mv | AT pingyenliu pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT liangyulin pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT hungjulin pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT chienhsunhsia pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT yirenhung pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT hungiyeh pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT taochengwu pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT juyichen pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT kuoliongchien pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy AT jawwenchen pitavastatinandatorvastatindoubleblindrandomizedcomparativestudyamonghighriskpatientsincludingthosewithtype2diabetesmellitusintaiwanpapagotstudy |